Evonik finalizes acquisition of Boehringer Ingelheim's RESOMER business
Based on its polymer platform EUDRAGIT®, the Pharma Polymers Business Line is developing and researching customer-specific solutions for oral delivery forms. By acquiring the new RESOMER® Product Line, Pharma Polymers is opening up an application field in parenteral delivery forms, for example, for formulating innovative biotechnological active substances. Thus, Evonik is following the diversification strategy of several key customers from the pharmaceuticals industry and is opening up for itself the market for functional medicinal products. RESOMER® polymers are based first of all on the natural monomers lactic acid and glycolic acid, and they are fully degradable. Based on RESOMER®, depot pharmaceutical forms can be formulated to release the active substance in the body over several months.
In recent years, Evonik has strengthened its position as a producer of active pharmaceutical substances. In the United States, it took over Eli Lilly’s more than 600-employee-strong Tippecanoe site. This facility produces active substances and the associated intermediates for the pharmaceuticals industry. A new medical products plant has been built in Nanning, China, too. Customers also benefit from the Group's global research and production network and the extensive services it offers.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.